<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210613051566N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-12-17</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Ultrasound‐Guided Median nerve Hydrodissection with Corticosteroid Injection in the treatment of mild to moderate Carpal Tunnel Syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Ultrasound‐Guided Median nerve Hydrodissection with Corticosteroid Injection in the treatment of mild to moderate Carpal Tunnel Syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60183</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Block randomization with help of www.sealedenvelope.com website. 
According to treatment groups, block sizes and list length, the website generates a list of random codes consisting of an English letter and digits.
These codes are printing the codes on a card, and placing the cards in a sealed envelope (SNOSE method). 
After generating the list, each code will be printed on one card that, after shuffling, are placed in envelopes. Each patient will be given an envelope to assign to one of the groups. Also, in a separate list, the person is assigned to the code taken out of the envelope, Blinding description: In this study participants and outcomes assessor are masked.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Carpal tunnel syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in this group will undergo a Ultrasound-guided Median nerve hydrodissection with corticosteroid injection. Total of 5cc solution consisting of 1cc of Triamcinolone acetonide (40mg), 1cc of lidocaine, and 3cc of saline is used. Using ultrasound guidance and aseptic technique, the needle will be inserted from an ulnar approach, then be angled deep to inject 2 ml of mixture for separating nerve from Flexor tendons beneath. The needle will then be angled superficial to the median nerve and 3ml of mixture will be injected to to peel the median nerve off the overlying flexor retinaculum. Intervention 2: Intervention group: Patients in this group will undergo a Ultrasound-guided Median nerve hydrodissection without corticosteroid injection. Total of 5cc solution consisting of 1cc of lidocaine, and 4cc of saline is used. Using ultrasound guidance and aseptic technique, the needle will be inserted from an ulnar approach, then be angled deep to inject 2 ml of mixture for separating nerve from Flexor tendons beneath. The needle will then be angled superficial to the median nerve and 3ml of mixture will be injected to to peel the median nerve off the overlying flexor retinaculum. Intervention 3: Control group: Patients in this group will undergo a routine and standard Corticosteroid injection for CTS treatment. Using ultrasound guidance and aseptic technique, the needle will be inserted from an ulnar approach, and 1ml of Triamcinolone acetonide (40mg) will be injected into the area above Median nerve without separating the nerve from surrounding structures.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data of the study participants will be evaluated for statistical analysis, and their results will be published in the form of an article.

When:
Immediately after the publication of the results in the form of a scientific article, the results of data analysis will be available to researchers at the request of the data.

To whom:
Researchers of this project and individuals who have the right to access the project data based on the written permission of the corresponding researcher can access the project data.

Conditions:
If the permission of the main researcher of the project is obtained with an acceptable justification and explanation, the data obtained from this project can be used.

Where to obtain:
Imam Khomeini Hospital Complex, Physical Medicine and Rehabilitation department, Dr Mohadese Azadvari

How to obtain:
A written request will be sent to the researcher in charge of the study with appropriate evidence and justification; Once approved by him, access to data and documents will be possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sahar Ghorbanpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.1. Aghili St. Aazodi Ave. Karimkhan St. Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1598684813</zip>
        <telephone>+98 21 8870 1551</telephone>
        <email>sahar.ghorbanpour@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohadese Azadvari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Physical medicine and rehabilitation department, Sina hospital, Hassan Abad square</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1418733141</zip>
        <telephone>+98 21 61190</telephone>
        <email>drazadvari@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Confirmed clinical and Electrophysiological diagnosis of Carpal Tunnel Syndrome with mild to moderate degree</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Confirmed clinical and Electrophysiological diagnosis of CTS with severe degree
Patients with suspicious of CTS mimic condition, including cervical radiculopathy, polyneuropathy, brachial plexopathy, thoracic outlet syndrome
Recent corticosteroid injection to the carpal tunnel within 6 months
Previous history of carpal tunnel surgical release
Steroid injection contraindications
Pregnancy
Cancer
Coagulopathy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Carpal tunnel syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in this group will undergo a Ultrasound-guided Median nerve hydrodissection with corticosteroid injection. Total of 5cc solution consisting of 1cc of Triamcinolone acetonide (40mg), 1cc of lidocaine, and 3cc of saline is used. Using ultrasound guidance and aseptic technique, the needle will be inserted from an ulnar approach, then be angled deep to inject 2 ml of mixture for separating nerve from Flexor tendons beneath. The needle will then be angled superficial to the median nerve and 3ml of mixture will be injected to to peel the median nerve off the overlying flexor retinaculum.</i_keyword>
      <i_keyword>Intervention group: Patients in this group will undergo a Ultrasound-guided Median nerve hydrodissection without corticosteroid injection. Total of 5cc solution consisting of 1cc of lidocaine, and 4cc of saline is used. Using ultrasound guidance and aseptic technique, the needle will be inserted from an ulnar approach, then be angled deep to inject 2 ml of mixture for separating nerve from Flexor tendons beneath. The needle will then be angled superficial to the median nerve and 3ml of mixture will be injected to to peel the median nerve off the overlying flexor retinaculum.</i_keyword>
      <i_keyword>Control group: Patients in this group will undergo a routine and standard Corticosteroid injection for CTS treatment. Using ultrasound guidance and aseptic technique, the needle will be inserted from an ulnar approach, and 1ml of Triamcinolone acetonide (40mg) will be injected into the area above Median nerve without separating the nerve from surrounding structures.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Boston carpal tunnel syndrome questionnaire (BCTQ). Timepoint: Pre-treatment, 1st, 3rd and 6th months after injection. Method of measurement: five-point rating scale questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Visual Analog Scale (VAS) for Pain. Timepoint: Pre injection, 2 weeks, 1, 3 and 6 months intervals. Method of measurement: Visual and numeric scale.</sec_outcome>
      <sec_outcome>Cross-sectional area of the Median nerve. Timepoint: Pre injection, 1, 3 and 6 months intervals. Method of measurement: Ultrasound device.</sec_outcome>
      <sec_outcome>Conduction Velocity, Distal Latency and Amplitude of Median nerve SNAP &amp; CMAP. Timepoint: Pre injection, 1, 3 and 6 months intervals. Method of measurement: EMG- NCV.</sec_outcome>
      <sec_outcome>Hand grip strength. Timepoint: Pre injection, 1, 3 and 6 months intervals. Method of measurement: Dynamometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-28</approval_date>
        <contact_name>Ethics committee of Tehran University of Medical Sciences, Sina hospital</contact_name>
        <contact_address>Room 605، Secretariat of the Ethics Committee in University Biomedical Research، Vice Chancellor for Research and Technology, 6th Floor, Central University Organization, Corner of Ghods St., Keshavarz Blvd. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
